228 related articles for article (PubMed ID: 28185693)
1. Advances in oral anticoagulation therapy - What's in the pipeline?
Rao PSS; Burkart T
Blood Rev; 2017 Jul; 31(4):205-211. PubMed ID: 28185693
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology and laboratory testing of the oral Xa inhibitors.
Samama MM; Meddahi S; Samama CM
Clin Lab Med; 2014 Sep; 34(3):503-17. PubMed ID: 25168939
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: rivaroxaban, apixaban, edoxaban and betrixaban].
Meddahi S; Samama MM
J Mal Vasc; 2014 May; 39(3):183-94. PubMed ID: 24650612
[TBL] [Abstract][Full Text] [Related]
4. Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy.
Finks SW; Trujillo TC; Dobesh PP
Ann Pharmacother; 2016 Jun; 50(6):486-501. PubMed ID: 26917821
[TBL] [Abstract][Full Text] [Related]
5. Measuring Direct Oral Anticoagulants.
Gosselin RC; Douxfils J
Methods Mol Biol; 2017; 1646():217-225. PubMed ID: 28804832
[TBL] [Abstract][Full Text] [Related]
6. Is it reasonable to use a lower DOACs dose in some patients with VTE? Yes.
Imberti D; Mastroiacovo D
Intern Emerg Med; 2017 Aug; 12(5):561-563. PubMed ID: 28647891
[TBL] [Abstract][Full Text] [Related]
7. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
Beyer-Westendorf J; Ageno W
Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
[TBL] [Abstract][Full Text] [Related]
8. Anticoagulants: What is new and what is the standard?
Lesko LJ
Clin Pharmacol Ther; 2016 Aug; 100(2):126-8. PubMed ID: 27197625
[TBL] [Abstract][Full Text] [Related]
9. Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum.
Siddiqui F; Hoppensteadt D; Jeske W; Iqbal O; Tafur A; Fareed J
Clin Appl Thromb Hemost; 2019; 25():1076029619847524. PubMed ID: 31088146
[TBL] [Abstract][Full Text] [Related]
10. Cancer-associated thrombosis - treatment and prevention with direct oral factor Xa inhibitors.
Grilusová K; Bolek T; Škorňová I; Staško J; Samoš M; Mokáň M
Klin Onkol; 2021; 34(4):283-290. PubMed ID: 34905929
[TBL] [Abstract][Full Text] [Related]
11. Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles.
Goto E; Horinaka S; Ishimitsu T; Kato T
Drug Metab Pharmacokinet; 2020 Feb; 35(1):151-159. PubMed ID: 32007354
[TBL] [Abstract][Full Text] [Related]
12. Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants.
Weitz JI; Jaffer IH
Pol Arch Med Wewn; 2016 Sep; 126(9):688-696. PubMed ID: 27592622
[TBL] [Abstract][Full Text] [Related]
13. The role of factor Xa inhibitors in venous thromboembolism treatment.
Cabral KP; Ansell JE
Vasc Health Risk Manag; 2015; 11():117-23. PubMed ID: 25673997
[TBL] [Abstract][Full Text] [Related]
14. Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism - The SWAN Study.
Hendriks T; McGregor S; Rakesh S; Robinson J; Ho KM; Baker R
PLoS One; 2020; 15(6):e0234048. PubMed ID: 32497116
[TBL] [Abstract][Full Text] [Related]
15. Laboratory measurement of the direct oral anticoagulants.
Dale BJ; Chan NC; Eikelboom JW
Br J Haematol; 2016 Feb; 172(3):315-36. PubMed ID: 26492202
[TBL] [Abstract][Full Text] [Related]
16. Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?
Gibson CM; Finks SW
Am J Med; 2017 Aug; 130(8):900-906. PubMed ID: 28390791
[TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapy with oral Xa inhibitors for venous thromboembolism.
Vanassche T; Vandenbriele C; Peerlinck K; Verhamme P
Expert Opin Pharmacother; 2015 Apr; 16(5):645-58. PubMed ID: 25554350
[TBL] [Abstract][Full Text] [Related]
18. Italian intersociety consensus on DOAC use in internal medicine.
Prisco D; Ageno W; Becattini C; D'Angelo A; Davì G; De Cristofaro R; Dentali F; Di Minno G; Falanga A; Gussoni G; Masotti L; Palareti G; Pignatelli P; Santi RM; Santilli F; Silingardi M; Tufano A; Violi F; ; ;
Intern Emerg Med; 2017 Apr; 12(3):387-406. PubMed ID: 28191610
[TBL] [Abstract][Full Text] [Related]
19. Establishing Edoxaban's Role in Anticoagulation.
Guirguis E; Brown D; Grace Y; Patel D; Henningfield S
J Pharm Pract; 2016 Jun; 29(3):228-38. PubMed ID: 27169733
[TBL] [Abstract][Full Text] [Related]
20. Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs.
Mikus G; Foerster KI; Schaumaeker M; Lehmann ML; Burhenne J; Haefeli WE
Clin Pharmacokinet; 2019 Sep; 58(9):1155-1163. PubMed ID: 30828771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
